NKARTA INC (NKTX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NKTX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NKTX | Director | 63 | ["Executive Vice President and Chief Business and Financial Officer of Zymeworks Inc.","Chief Financial and Business Officer of Tenaya Therapeutics, Inc.","Chief Financial Officer of Adverum Biotechnologies, Inc.","Chief Executive Officer of Adverum Biotechnologies, Inc.","Director of Adverum Biotechnologies, Inc.","President of Adverum Biotechnologies, Inc.","Senior positions at Diadexus, Inc., Transcept Pharmaceuticals, Inc., NetApp, Inc., Exelixis, Inc., Novartis AG, Chiron, and KPMG","B.S. in business administration and accounting from Chapman University","Executive M.B.A. from St. Mary’s College","Certified Public Accountant (inactive status)","Over 20 years of experience in the biotechnology industry"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Leone Patterson, M.B.A. has served on our Board of Directors since April 2020. Ms. Patterson most recently served as Executive Vice President and Chief Business and Financial Officer of Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company, until January 2026. Previously, Ms. Patterson was Chief Financial and Business Officer of Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company, from June 2021 to August 2024. Prior to Tenaya, Ms. Patterson held several roles at Adverum Biotechnologies, Inc. (NASDAQ: ADVM) including Chief Financial Officer from June 2016 to May 2018, Chief Executive Officer from May 2018 to June 2020, Director from October 2018 to June 2020, and President from December 2019 to June 2021. Ms. Patterson has held various senior positions at Diadexus, Inc., Transcept Pharmaceuticals, Inc., NetApp, Inc. (NASDAQ: NTAP), Exelixis, Inc. (NASDAQ: EXEL), Novartis AG (NYSE: NVS), Chiron (acquired by Novartis AG), and KPMG. Ms. Patterson has also served on the board of directors of Kalaris Therapeutics (NASDAQ: KLRS) since April 2025. Ms. Patterson previously served on the Oxford Biomedica plc (LSE: OXB) board of directors from April 2023 until December 2024. Ms. Patterson earned a B.S. in business administration and accounting from Chapman University and an Executive M.B.A. from St. Mary s College. Ms. Patterson is also a Certified Public Accountant (inactive status).